28.35

4.27% 1.16

After Hours: 28.35

Viridian Therapeutics Inc (VRDN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Viridian Therapeutics Inc stock is traded at $28.35, with a volume of 1.15M. It is up +4.27% in the last 24 hours and down -2.04% over the past month. Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Previous Close:

$27.19

Open:

$27.24

24h Volume:

1.15M

Relative Volume:

0.82

Market Cap:

$2.90B

Revenue:

$70.85M

Net Income/Loss:

$-324.22M

P/E Ratio:

-7.4478

EPS:

-3.8065

Net Cash Flow:

$-277.36M

1W Performance:

+2.24%

1M Performance:

-2.04%

6M Performance:

+48.58%

1Y Performance:

+91.55%

1-Day Range:

$27.10

$28.59

1-Week Range:

$26.27

$28.59

52-Week Range:

$9.90

$34.29

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name

Viridian Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

617.272.4600

Address

221 CRESCENT STREET, WALTHAM

Employee

252

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

VRDN's Discussions on Twitter

Compare VRDN vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRDN Viridian Therapeutics Inc	28.35	2.78B	70.85M	-324.22M	-277.36M	-3.8065
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Reiterated	Wedbush	Outperform
Dec-03-25	Initiated	William Blair	Outperform
Nov-24-25	Initiated	Truist	Buy
Aug-25-25	Resumed	Jefferies	Buy
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Jun-06-24	Initiated	Goldman	Buy
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-14-23	Initiated	BTIG Research	Buy
Jun-14-23	Resumed	Credit Suisse	Outperform
May-30-23	Initiated	RBC Capital Mkts	Outperform
Apr-17-23	Initiated	Wells Fargo	Overweight
Mar-30-23	Initiated	Stifel	Buy
Dec-19-22	Initiated	Cowen	Outperform
Dec-19-22	Initiated	Needham	Buy
Dec-16-22	Initiated	Credit Suisse	Outperform
Dec-01-22	Initiated	H.C. Wainwright	Buy
Jun-23-22	Initiated	B. Riley Securities	Buy
Nov-18-21	Initiated	SVB Leerink	Outperform
Oct-12-21	Initiated	Evercore ISI	Outperform
Jan-25-21	Initiated	Ladenburg Thalmann	Buy

View All

Viridian Therapeutics Inc Stock (VRDN) Latest News

Mar 25, 2026

Volatility Watch: Will Viridian Therapeutics Inc benefit from geopolitical trends2026 Macro Impact & Fast Exit Strategy with Risk Control - baoquankhu1.vn

Mar 25, 2026

Patterns Watch: What is the implied volatility of Viridian Therapeutics IncMarket Risk Analysis & Accurate Intraday Trade Tips - baoquankhu1.vn

Mar 25, 2026

Mar 22, 2026

Hudson Bay Capital Management LP Raises Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Mar 22, 2026

Behavioral Patterns of VRDN and Institutional Flows - Stock Traders Daily

Mar 22, 2026

Mar 21, 2026

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know - AOL.com

Mar 21, 2026

Fund Sells $81M in Viridian Stock: Q4 2025 Portfolio ShiftNews and Statistics - IndexBox

Mar 21, 2026

Kynam Capital Management Cuts Viridian Stake by Over $81 Million - Intellectia AI

Mar 21, 2026

This fund recently reduced its holding in a Viridian stock by more than $80 million. What does this mean for investors? - Bitget

Mar 21, 2026

Mar 20, 2026

Is It Too Late To Consider Viridian Therapeutics (VRDN) After Its 82% One-Year Surge? - Yahoo Finance

Mar 20, 2026

Is It Time To Reassess Viridian Therapeutics (VRDN) After Its Strong 1-Year Share Price Run? - Sahm

Mar 20, 2026

Mar 19, 2026

Eyes On Viridian: Major FDA And Trial Milestones On The Horizon - RTTNews

Mar 19, 2026

Mar 18, 2026

Viridian Therapeutics Hits Day High with Strong 7.14% Intraday Surge - Markets Mojo

Mar 18, 2026

Mar 17, 2026

Setup Watch: What are the future prospects of Viridian Therapeutics IncWeekly Investment Recap & Expert Approved Trade Ideas - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Stocks Flashing Renewed Technical Strength: Viridian Therapeutics - MSN

Mar 16, 2026

Dow Update: Will Viridian Therapeutics Inc outperform its industry peers2026 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn

Mar 16, 2026

Mar 15, 2026

Commodore Capital LP Cuts Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat

Mar 15, 2026

VRDN SEC FilingsViridian Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 15, 2026

Mar 14, 2026

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 14, 2026

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com

Mar 14, 2026

Mar 13, 2026